VU6000918（Cat No.:I038167）is a selective and potent inhibitor of the sodium-dependent dopamine transporter (DAT), a key protein involved in dopamine reuptake and regulation of dopaminergic neurotransmission. By blocking DAT activity, VU6000918 increases extracellular dopamine levels, making it a valuable tool for studying dopaminergic signaling in neurological and psychiatric disorders such as Parkinson’s disease, ADHD, and addiction. Unlike traditional DAT inhibitors, VU6000918 offers improved selectivity and pharmacokinetic properties, allowing for precise modulation of dopamine dynamics. It supports preclinical research into dopamine-related pathologies and the development of targeted therapeutic interventions.